This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2018 Dec 20;379(25):2463-2464.

doi: 10.1056/NEJMe1813684.

A Glimmer of Hope for Pancreatic Cancer

Hedy L Kindler¹

Affiliations

PMID: 30575492
DOI: 10.1056/NEJMe1813684

Editorial

A Glimmer of Hope for Pancreatic Cancer

Hedy L Kindler. N Engl J Med. 2018.

. 2018 Dec 20;379(25):2463-2464.

doi: 10.1056/NEJMe1813684.

Author

Hedy L Kindler¹

Affiliation

¹ From the Section of Hematology-Oncology, University of Chicago Medicine, Chicago.

PMID: 30575492
DOI: 10.1056/NEJMe1813684

No abstract available

PubMed Disclaimer

Comment on

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. Conroy T, et al. N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775. N Engl J Med. 2018. PMID: 30575490 Clinical Trial.

Similar articles

[S‑1 versus gemcitabine for adjuvant therapy in pancreatic cancer].
Strobel O, Büchler MW. Strobel O, et al. Chirurg. 2016 Oct;87(10):892. doi: 10.1007/s00104-016-0282-2. Chirurg. 2016. PMID: 27586535 German. No abstract available.
Survival for patients with pancreatic cancer after addition of gemcitabine to fluorouracil chemoradiation.
Vikram B. Vikram B. JAMA. 2008 Jun 25;299(24):2852; author reply 2852-3. doi: 10.1001/jama.299.24.2852-b. JAMA. 2008. PMID: 18577724 No abstract available.
Survival for patients with pancreatic cancer after addition of gemcitabine to Fluorouracil chemoradiation.
Fujita T. Fujita T. JAMA. 2008 Jun 25;299(24):2852; author reply 2852-3. doi: 10.1001/jama.299.24.2852-a. JAMA. 2008. PMID: 18577725 No abstract available.
[Results of gemcitabine hydrochloride in the treatment for pancreatic cancer].
Tsukagoshi S. Tsukagoshi S. Gan To Kagaku Ryoho. 2001 Oct;28(10):1461-7. Gan To Kagaku Ryoho. 2001. PMID: 11681259 Review. Japanese.
[Conservative therapy for pancreatic cancer].
Ito T, Arita Y, Kawabe K, Hisano T, Nawata H. Ito T, et al. Nihon Naika Gakkai Zasshi. 2004 Jan 10;93(1):64-9. doi: 10.2169/naika.93.64. Nihon Naika Gakkai Zasshi. 2004. PMID: 14968576 Review. Japanese. No abstract available.

See all similar articles

Cited by

A novel antisense lncRNA NT5E promotes progression by modulating the expression of SYNCRIP and predicts a poor prognosis in pancreatic cancer.
Zhang P, Cao M, Zhang Y, Xu L, Meng F, Wu X, Xia T, Chen Q, Shi G, Wu P, Chen L, Lu Z, Yin J, Cai B, Cao S, Miao Y, Jiang K. Zhang P, et al. J Cell Mol Med. 2020 Sep;24(18):10898-10912. doi: 10.1111/jcmm.15718. Epub 2020 Aug 8. J Cell Mol Med. 2020. PMID: 32770626 Free PMC article.
PAC-5 Gene Expression Signature for Predicting Prognosis of Patients with Pancreatic Adenocarcinoma.
Kim J, Jo YH, Jang M, Nguyen NNY, Yun HR, Ko SH, Shin Y, Lee JS, Kang I, Ha J, Choi TG, Kim SS. Kim J, et al. Cancers (Basel). 2019 Nov 7;11(11):1749. doi: 10.3390/cancers11111749. Cancers (Basel). 2019. PMID: 31703415 Free PMC article.
Linderalactone Suppresses Pancreatic Cancer Development In Vitro and In Vivo via Negatively Regulating PI3K/AKT Signaling Pathway.
Xu D, Tian M, Chen W, Bian Y, Xia X, Liu Q, Zheng L, Zhang X, Shen H. Xu D, et al. J Oncol. 2022 Aug 4;2022:8675096. doi: 10.1155/2022/8675096. eCollection 2022. J Oncol. 2022. PMID: 35966890 Free PMC article.
Complex Role of Microbiome in Pancreatic Tumorigenesis: Potential Therapeutic Implications.
Amara S, Yang LV, Tiriveedhi V, Muzaffar M. Amara S, et al. Cells. 2022 Jun 11;11(12):1900. doi: 10.3390/cells11121900. Cells. 2022. PMID: 35741028 Free PMC article. Review.
LncRNA ZNFTR functions as an inhibitor in pancreatic cancer by modulating ATF3/ZNF24/VEGFA pathway.
Li W, Han S, Hu P, Chen D, Zeng Z, Hu Y, Xu F, Tang J, Wang F, Zhao Y, Huang M, Zhao G. Li W, et al. Cell Death Dis. 2021 Sep 3;12(9):830. doi: 10.1038/s41419-021-04119-3. Cell Death Dis. 2021. PMID: 34480024 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information